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Background: Recent efforts in osteoarthritis (OA) research have highlighted synovial inflammation and involvement of
immune cells in disease onset and progression. We sought to establish the in-vivo immune response in collagenase-
induced OA and investigate the ability of human mesenchymal stem cells (hMSCs) overexpressing viral interleukin
10 (vIL-10) to modulate immune populations and delay/prevent disease progression.
Methods: Eight-week-old male C57BL/6 mice were injected with 1 U type VII collagenase over two consecutive days.
At day 7, 20,000 hMSCs overexpressing vIL-10 were injected into the affected knee. Control groups comprised of
vehicle, 20,000 untransduced or adNull-transduced MSCs or virus alone. Six weeks later knees were harvested for
histological analysis and popliteal and inguinal lymph nodes for flow cytometric analysis.
Results: At this time there was no significant difference in knee OA scores between any of the groups. A trend toward
more damage in animals treated with hMSCs was observed. Interestingly there was a significant reduction in the
amount of activated CD4 and CD8 T cells in the vIL-10-expressing hMSC group.
Conclusions: vIL-10-overexpressing hMSCs can induce long-term reduction in activated T cells in draining lymph
nodes of mice with collagenase-induced OA. This could lead to reduced OA severity or disease progression over the
long term.
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Although osteoarthritis (OA) is typically characterised
by loss or damage to articular cartilage, inflammation of
the synovial membrane is a prevalent feature believed to
contribute to both symptoms and disease progression.
Thickening of the synovial membrane has been identified
in patients with early-stage OA, and increased vascu-
lar density and cellular infiltration of the synovium is* Correspondence: e.farrell@erasmusmc.nl
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Macrophages localised to the synovial lining are primary
mediators of inflammation in the joint, responsible for the
production of pro-inflammatory cytokines such as tumour
necrosis factor alpha (TNF-α) and interleukin (IL)-1β,
which can induce destructive processes in neighbouring
cartilage [2, 3]. T lymphocytes are the most abundant infil-
trating immune cells present in OA synovium, with both
CD4+ effector T cells and CD8+ cytotoxic T cells observed
in the sublining layer [4, 5]. Moreover, a role of CD4+ T
cells in the pathogenesis of OA has been identified, through
the induction of MIP-1γ and osteoclastogenesis [6].
Mesenchymal stem cells (MSCs) have been considered a
promising cell source for the repair of damaged cartilage
in OA, due to their chondrogenic differential potential [7].is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
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hance intrinsic tissue repair through the release of trophic
factors which act to modulate inflammatory processes or
recruit endogenous progenitor cells [8, 9]. MSCs have the
ability to polarise pro-inflammatory macrophages towards
an anti-inflammatory phenotype and suppress T-cell
proliferation, and have been previously reported to exert
anti-inflammatory effects on human osteoarthritic syno-
vium in vitro [10–12]. Xenotransplantation of human
MSCs (hMSCs) has enhanced meniscal regeneration and
prevented OA progression in rats following hemi-
meniscectomy, with no significant difference observed be-
tween the reparative effects of xenogeneic or rat syngeneic
MSCs [13]. Furthermore, allogeneic MSCs have been
shown to prevent post-traumatic arthritis following intra-
articular fracture in mice; however, an effect of hMSC
delivery on synovial hyperplasia was not observed [14].
Although intra-articularly delivered adipose-derived stem
cells have been reported to migrate to the synovium,
reduce synovial lining thickness and decrease cartilage
damage in a murine collagenase-induced OA model [15],
the ability of bone marrow-derived hMSCs to alter the
inflammatory environment in OA and subsequently delay
disease progression requires further investigation.
One factor of particular interest to target OA-associated
inflammatory processes is IL-10. IL-10 is a 34 kDa
homodimeric cytokine produced by activated macro-
phages, T-helper type 2 cells and B cells, and is associated
with diverse biological responses [12, 16–18]. IL-10 can
suppress pro-inflammatory cytokine production; for
example, TNF-α, IL-1β and IL-6 produced by activated
macrophages, monocytes and T-helper type 1 cells re-
spectively [17, 19]. Furthermore, IL-10 reduces monocyte
expression of major histocompatibility complex (MHC)
class II, resulting in decreased antigen presentation and
subsequent inhibition of T-cell proliferation [20]. In
addition to its immunosuppressive properties, IL-10 can
stimulate B cells to increase MHC class II expression and
immunoglobulin production, as well as enhance mast cell
growth [21–23]. Human IL-10 exhibits 84 % amino acid
sequence homology to an open reading frame product of
Epstein–Barr virus, termed viral IL-10 (vIL-10) [24]. Al-
though vIL-10 displays comparable immunosuppressive
activity to human IL-10, it lacks particular stimulatory
functions [22]. Furthermore, adenoviral-mediated gene
transfer of vIL-10 or overexpression by retrovirally trans-
duced MSCs has been reported to significantly decrease
the frequency of arthritis, delay the onset and reduce the
severity of arthritic symptoms in a murine collagen-
induced rheumatoid arthritis model [25, 26].
In the present study, we have investigated the ability of
xenogeneic hMSCs overexpressing vIL-10 to modulate the
inflammatory environment and alter disease progression in
a murine collagenase-induced OA model. Overexpressionwas induced using an adenoviral construct with transduced
hMSCs referred to as AdIL-10 MSCs. This model is associ-
ated with joint ligament damage resulting in instability
[27], as well as synovial activation compared with other
instability-related OA models [28]. Intra-articular injection
of 1 U collagenase was administered over two consecutive
days to induce mild structural changes and OA progres-
sion in order to achieve a suitable model to evaluate the
potential of an anti-inflammatory component to attenuate
OA pathogenesis. Our findings highlight modulatory
activity of hMSCs adenovirally transduced to overexpress
vIL-10 on the levels of naive and activated CD4+ and CD8+
T cells in vivo during OA progression.Methods
Isolation and culture of hMSCs
hMSCs were obtained from bone marrow aspirates
taken from the iliac crest of healthy human donors. All
procedures were performed with informed consent and
approved by the Clinical Research Ethical Committee at
University College Hospital, Galway, Ireland. The cells
were isolated based on plastic adherence as described pre-
viously [29] and expanded in alpha-Minimum Essential
Medium (α-MEM; Life Technologies, Zoetermeer, the
Netherlands) containing 10 % pre-screened foetal bovine
serum (FBS; Hyclone, South Logan, UT, USA), 1 % penicil-
lin/streptomycin and 1 ng/ml recombinant human basic
fibroblast growth factor (FGF2; PeproTech, London, UK).
Upon reaching confluency, hMSCs were subcultured to
passage 3 for adenoviral transduction. Three MSC donors
were used for the in-vitro experiments and one of these
was used for the in-vivo study with eight replicates per
condition.Adenoviral transduction of hMSCs
Adenoviral transduction of hMSCs was performed using
the lanthanide-based method as described previously [30].
hMSCs were seeded at a density of 6 × 103 cells/cm2 in a
T175 flask 24 h prior to transduction. Calculated amounts
of adenoviral vectors expressing vIL-10 (AdIL-10) or Null
virus (AdNull) were added to serum-free α-MEM medium
to generate a final multiplicity of infection of 100. LaCl3
(Sigma-Aldrich, Wicklow, Ireland) was dissolved in deio-
nised water to generate a 0.4 M stock solution and stored
at 4 °C. A working solution of 0.04 mM LaCl3 was gener-
ated following the addition of an appropriate volume of a
0.4 M stock to serum-free medium. An equal volume of
0.04 mM LaCl3 solution was added to the virus solution,
mixed gently and incubated at room temperature for 30
minutes. hMSCs were incubated with the LaCl3/virus
mixture for 3 h, following which cells were washed twice
with serum-containing medium. Cells were harvested for
subsequent experiments 48 h post transduction.
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AdIL-10 MSC CM
Macrophages were seeded at a density of 4 × 105 cells/ml in
a 24-well plate, in RAW264.7 culture medium (Dulbecco’s
modified Eagle’s medium (4500 ng/ml glucose), 2 mM
glutamine, 10 % FBS and 1 % penicillin/streptomycin).
Lipopolysaccharide (LPS; Sigma-Aldrich) was added to the
cell culture medium at a final concentration of 0.5 ng/ml.
Supernatant was harvested at 2, 4, 6, 12 and 24 h post LPS
stimulation and centrifuged at 400 × g for 5 minutes to
pellet any debris. TNF-α levels in the supernatant were
measured with a commercial human TNF-α DuoSet ELISA
kit according to the manufacturer’s instructions (R&D
Systems, Minneapolis, Minnesota). To assess the effect of
MSC conditioned medium (CM) (n = 3 donors) on TNF-α
production by LPS-activated mouse macrophages, the vIL-
10 concentration was quantified in the CM from AdIL-10-
transduced MSCs by ELISA (purified rat anti-human vIL-
10 (capture antibody); BD Biosciences; and biotinylated rat
anti-human vIL-10 (detection antibody); BD Biosciences,
Oxford England) diluted to ensure addition of 100 ng/
ml vIL-10 per well. Equal volumes (compared with
AdIL-10 MSC CM) of untransduced MSC CM and
AdNull-transduced MSC CM were used as controls.T-cell proliferation assays and mixed lymphocyte reaction
cultures
Lymphocytes were obtained from the lymph nodes and
spleens of C57BL/6 mice. Lymphocytes were washed
with 0.1 % BSA/PBS and stained in pre-warmed (37 °C) 10
μM Vybrant CFDA SE (carboxy-fluorescein diacetate, suc-
cinmidyl ester (CFSE))/PBS staining solution (Invitrogen,
Carlsbad, CA, USA) as per the manufacturer’s instructions.
Then 1 × 105 CFSE-stained T cells were stimulated with
phorbol myristate acetate (5 ng/ml) and ionomycin
(400 ng/ml) in T-cell medium (RPMI 1640 supple-
mented with 10 % FCS, 50 μM β-mercaptoethanol,
100 U/ml penicillin, 0.1 mg/ml streptomycin, 1 mM
sodium pyruvate and 2 mM L-glutamine). Lymphocytes
were co-cultured with human untransduced MSCs,
AdNull MSCs and AdIL-10 MSCs (n = 3 donors) at
MSC:T-cell ratios ranging from 1:400 to 1:10 in a humidi-
fied incubator for 4 days. Mouse T-cell proliferation (CFSE
quantification) was measured by flow cytometry (FACS
Canto; BD Biosciences).
For mouse mixed lymphocyte reactions, human
untransduced MSCs, AdNull MSCs and AdIL-10 MSCs
(n = 3 donors) were plated in 96-well round-bottom
plates. CFSE-labelled untreated lymphocytes isolated
from C57BL/6 mice were used as responders, at ratios of
1:5, 1:10 and 1:50 MSC:T cells. A total of 4 × 103, 2 × 104
or 4 × 104 stimulating cells were co-cultured with 2 × 105
CFSE-labelled responding lymphocytes for 5 days. T-cellproliferation was analysed on a FACS Canto (BD
Biosciences).
OA model
All procedures were approved by the Animal Care and
Research Ethics Committee of the National University of
Ireland, Galway and conducted under licence issued by
the Department of Health & Children, Ireland. Eight-
week-old male C57BL/6 mice were supplied by Charles
River Laboratories, Ballina, Ireland, UK. All animals were
kept on a 12 h light/dark cycle with ad libitum access to
water and standard laboratory chow. Eight animals were
randomly assigned to each treatment group with the treat-
ment leg (left or right) also chosen randomly. All animals
were coded and scorers were blinded to the treatment.
To induce OA, 1 U of highly purified bacterial type
VII collagenase (Sigma-Aldrich) in 6 μl of physiological
saline (vehicle) was injected into the knee joint of mice
twice over two consecutive days (totalling 2 U). Animals
were anaesthetised using isoflurane and given a subcuta-
neous injection of buprenorphine (Temgesic, 0.01 mg/kg
body weight) prior to collagenase injection. One week
later animals were injected with one of five conditions in
a volume of 6 μl: vehicle alone, 2 × 104 MSCs, AdIL-10-
transduced MSCs, AdNull-transduced MSCs or the
equivalent amount of virus used to transduce 2 × 104
cells suspended in the vehicle. The cell number was
chosen based on ELISA-based analysis of the amount of
vIL-10 produced by the hMSCs and corresponded to
100 ng/ml vIL-10 production. Seven weeks after the in-
duction of OA, animals were euthanised and the joints
were removed, fixed in 10 % formalin and subsequently
decalcified in 10 % EDTA. Popliteal and inguinal lymph
nodes were also harvested and analysed for T-cell
markers by flow cytometry. A timeline of the model is
provided in Additional file 1: Figure S1.
Histological scoring of sections
Paraffin sections (5 μm) were stained with safranin O and
fast green. Sections were deparaffinised by immersion of
slides twice in 100 % xylene for 5 minutes, and rehydrated
to distilled water following immersion in 100 % ethanol
for 2 minutes and for 1 minute in 95 % and 70 % ethanol.
Sections were stained utilising 0.02 % fast green for 4
minutes, acetic acid for 3 seconds and 0.1 % safranin O
for 6 minutes. Following dehydration, sections were
mounted with DPX (all Sigma-Aldrich). To score the
femurs and tibiae, six sections per animal, spaced approxi-
mately 100 μm apart, were scored by three independent,
blinded observers. The scoring was based upon the semi-
quantitative grading system designed by the OARSI
working group [31] with damage ranging from 0 (no
damage) to 6 (complete denudation of the cartilage). All
scores for each knee compartment (lateral and medial
Table 1 Flow cytometry antibodies used as markers of interest
Antibody Flurophore Antibody
dilution
factor
Biolegend
catalogue
number
Anti-mouse CD8a PE/Cy7 1:100 100721
Anti-mouse CD4 APC 1:120 100411
Anti-mouse CD25 FITC 1:60 101907
Anti-mouse/human CD11b Alexa Fluor® 647 1:60 101220
Anti-mouse Ly6C PerCP/Cy5.5 1:50 128011
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were then averaged for the three observers. To score the
amount of synovial inflammation, a grading of 0–3 was
used, with 0 indicating normal synovium with one or two
layers of cells and 3 being several cell layers thick. Grades
1 and 2 fell in between these two categories. Finally a total
knee damage score was generated by summing all scores
for the six compartments for each knee. Representative
images of safranin O-stained slides are available in
Additional file 2: Figure S2.
Thionine staining
Paraffin sections (5 μm) were de-waxed and redehydrated
in xylene and decreasing concentrations of alcohol (100 %,
96 % and 70 % twice each for 5 minutes respectively).
Samples were then stained in 0.04 % thionine in 0.01 M
aqueous sodium acetate pH 4.5 for 5 minutes. They were
then differentiated in 70 % ethanol for 10 seconds, rinsed
in 96 % ethanol and then taken through 100 % ethanol
and xylene. Slides were mounted with Entellan.
Multiplex ELISA
To assess monocyte chemoattractant protein-1 (MCP-1)
levels in serum samples harvested at 7 weeks post induction
of OA, a commercially available chemiluminescent array
was utilised (16-plex mouse cytokine screen; Quansys
Biosciences, Logan, Utah, US). Mice were randomised and
serum from two animals per treatment group was pooled
and stored at −80 °C until use. Briefly, an 8-point standard
curve was prepared using antigen standard provided, and
serum samples were diluted 1:2 in sample diluent. Then
50 μl of sample or standard was added to each well of a
pre-antibody-coated 96-well plate. The plate was covered
with a plate seal, and placed on a plate shaker at 500 RPM
for 1 h at room temperature. Following sample incubation,
the plate was washed three times with wash buffer and
50 μl per well of Detection Mix was added. The plate was
covered with a new seal, and returned to the plate shaker
for 1 h at 500 RPM at room temperature. Following six
washes, 50 μl of 1× streptavidin–HRP was added per well,
and the plate was incubated at room temperature for 15
minutes with shaking at 500 RPM. Following this incuba-
tion period, substrate A (hydrogen peroxide) and substrate
B (signal enhancer) were mixed in a 1:1 ratio, and 50 μl
was added per well. Imaging was performed immediately
using a Fluorchem imager (Alpha Innotech, Dublin,
Ireland) and the image was analysed using Q-View
software, version 2.15 (Quansys Biosciences). All other
cytokines in the array were below detectable levels.
Analysis of T-cell subsets from the draining lymph nodes
Popliteal and inguinal lymph nodes were removed from
C57BL/6 mice (ipsilateral side). Single cell suspensions
were obtained from each lymph node from each animalas described previously [32]. Mice were randomised and
lymph nodes from two animals per treatment group
were combined for T-cell analysis, with the exception of
one AdIL-10 virus-treated animal which appears as a
singlet due to the macroscopic observation of a large
haematoma and swelling above the treated knee joint
(thus creating a fifth data point in this group). Cell
suspensions were stained according to Table 1 for cell
surface expression of CD4, CD8 and CD25 to character-
ise individual T-cell subsets. CD4 identifies T-helper cells
while CD8 identifies cytotoxic T cells. Cell surface expres-
sion of CD25 was used as a marker of T-cell activation
[33]. For assessment of myeloid cells, popliteal lymph
nodes from two animals and inguinal lymph nodes from
four animals were pooled, because of low cell number.
Cell suspensions were also stained for expression of
CD11b (Alex Fluor® 647) and Ly6C (Peridinin Chlorophyll
Protein Complex (PerCP)/Cy5.5) (Table 1; Biolegend,
Dublin, Ireland) as markers of myeloid cells and inflam-
matory monocytes, respectively [34]. Samples were ana-
lysed on a FACS Canto cytometer (BD Biosciences).
Statistical analysis
In-vitro data were analysed by one-way or two-way
ANOVA (Fig. 1) followed by Bonferroni’s post-hoc test.
Knee scores and FACS data were analysed by Kruskal–
Wallis test followed by Dunn’s multiple comparisons test.
Results
AdIL-10-transduced hMSCs are immunomodulatory and
not immunogenic towards murine lymphocytes
To confirm the immunomodulatory potential of a xeno-
geneic source of MSCs, the ability of untransduced,
AdNull-transduced and AdIL-10-transduced hMSCs to
suppress the proliferation of stimulated C57BL/6
lymphocytes in vitro was determined. Untransduced,
AdNull-transduced and AdIL-10-transduced hMSCs
significantly reduced the proliferation of stimulated
lymphocytes (at greater than five generations) compared
with untreated cells (Fig. 1a; p < 0.001, n = 3). Further-
more, AdIL-10-transduced hMSCs showed a trend
towards decreased proliferation compared with untrans-
duced cells, but this effect was not significant. At three
Fig. 1 AdIL-10-transduced MSCs are immunomodulatory and not immunogenic. a To confirm the immunomodulatory potential of hMSCs on activated
murine lymphocytes, untransduced, AdNull-transduced and AdIL-10-transduced hMSCs were co-cultured with ionomycin and PMA-stimulated C57BL/6
lymphocytes for 4 days at a ratio of 1:10. Murine lymphocyte proliferation was measured by CFSE dilution and flow cytometric detection of CFSE
fluorescent peaks. Untransduced, AdNull-transduced and AdIL-10-transduced MSCs reduced the proliferation of stimulated lymphocytes, confirming their
immunosuppressive capacity. Values represent the mean ± SD of three biological replicates. Statistical analysis was performed using one-way ANOVA,
followed by Bonferroni’s multiple comparisons test. ***p< 0.001, indicating a significant difference compared with non-co-cultured stimulated lymphocytes.
b To assess potential immunostimulatory activity of hMSCs, untransduced, AdNull-transduced and AdIL-10-transduced hMSCs were co-cultured with
unstimulated C57BL/6 lymphocytes for 5 days, at a ratio of 1:5. Despite their xenogeneic origin, hMSCs did not induce proliferation of unstimulated C57BL/
6 lymphocytes beyond basal levels. c To confirm immunosuppressive activity of vIL-10 overexpressed by AdIL-10-transduced MSCs, LPS-stimulated murine
macrophages (RAW264.7) were treated with conditioned medium (CM) from untransduced, AdNull-transduced or AdIL-10-transduced hMSCs (100 ng/ml
vIL-10), or 100 ng/ml recombinant vIL-10 (rvIL-10) alone. CM harvested from AdIL-10-transduced MSCs as well as rvIL-10 significantly reduced TNF-α
production by LPS-activated macrophages. Values represent the mean ± SD of three biological replicates. Statistical significance was determined by a
one-way ANOVA with Bonferroni’s multiple comparisons test. *p< 0.05 **p< 0.005, ***p< 0.001. Asterisks indicate significantly different from AdIL-10 MSC
CM. LPS lipopolysaccharide, MSC mesenchymal stem cell, TNF-α tumour necrosis factor alpha
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showed a significant decrease in proliferation rate
compared with stimulated but untreated splenocytes
(data not shown). Given the xenogeneic source of the
hMSCs we also tested the immunogenicity of these cells
in culture with unstimulated splenocytes. No significant
increase in splenocyte proliferation was observed with
the addition of human cells whether these were MSCs,
AdNull-transduced MSCs or AdIL-10-transduced MSCs
(Fig. 1b; p = 0.9854, n = 3). This indicated that, at least
in vitro, hMSCs were not immunogenic.AdIL-10-transduced hMSC CM is anti-inflammatory
To confirm that vIL-10 present in CM harvested from
transduced hMSCs was anti-inflammatory, the effect on
TNF-α production by LPS-stimulated RAW264.7 mac-
rophages was determined. Macrophages were stimulated
with 0.5 ng/ml LPS alone, or co-incubated with LPS and
AdIL-10, AdNull or untransduced MSC CM, or mediumcontaining an equivalent concentration of recombinant
vIL-10 (100 ng/ml). At 4, 6 and 12 h post LPS stimula-
tion there was a significant decrease in the amount of
TNF-α production by AdIL-10 CM and recombinant
vIL-10-treated macrophages compared with LPS only
(Fig. 1c; 1.791 ± 0.21 ng/ml in LPS only vs 0.628 ±
0.08 ng/ml in AdIL-10-transduced MSC CM at 12 h,
p < 0.001, n = 3). Treatment of the RAW264.7 cells
with CM from untransduced or AdNull-transduced
MSCs did not significantly reduce the levels of TNF-
α production compared with samples treated with
LPS only (1.791 ± 0.21 ng/ml in LPS only vs 1.456 ±
0.36 ng/ml in untransduced hMSC CM at 12 h).vIL-10-overexpressing hMSCs induce long-lasting reduction
in activated T cells
To determine the immunomodulatory effect of vIL-10-
overexpressing hMSCs in vivo during OA development,
popliteal and inguinal lymph nodes were harvested 6
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etry for CD4, CD8 and the activation marker CD25.
Quantification of vIL-10 release from AdIL-10-
transduced MSCs in culture prior to injection showed
that AdIL-10-transduced cells produced 0.858 μg/ml of
AdIL-10 vs 0 ng/ml in both the untransduced and
AdNull-transduced MSCs. A significant effect of injec-
tion of AdIL-10-transduced MSCs on the presence and
activation state of CD4+ and CD8+ T cells was observed.
In the popliteal lymph nodes we observed a significant
reduction in the percentage of CD4+ T cells in the
AdIL-10 MSC group compared with the AdIL-10 only
group (Fig. 2a; 43.9 ± 11.6 % vs 25 ± 2.8 %; p = 0.0314). In
the inguinal lymph nodes both the AdIL-10 virus aloneVe
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Farrell et al. Stem Cell Research & Therapy  (2016) 7:74 Page 7 of 11IL-4 were undetectable in serum harvested from animals
in all treatment groups at the experimental end point, as
determined by multiplex ELISA (data not shown).
Additionally, levels of CD11b+ and CD11b+ Ly6C hi cells
in the popliteal lymph nodes (markers of pro-inflammatory
monocytes) were similar in all pooled samples from each
treatment group (Additional file 3: Figure S3A). However, a
trend towards decreased levels of CD11b+ and CD11b+
Ly6C hi cells was observed in the inguinal lymph nodes
following treatment with AdIL-10 virus alone. Levels of
MCP-1 in serum harvested from animals at the experimen-
tal end point were similar between each treatment group
(Additional file 3: Figure S3B).Injection of hMSCs does not prevent OA development or
progression
To assess the effect of AdIL-10-transduced hMSCs on
OA progression, knees treated with collagenase at time
0 and hMSCs at day 7 were harvested, sectioned and
stained with thionine 6 weeks after injection of the cells.
At this time point there was no significant difference ob-
served between the amount of damage in vehicle-treated
knees compared with any other group in any compart-
ment (Fig. 4a–d). All knees showed changes to both the
cartilage and synovium, with more damage observed in
the medial compartment compared with the lateral.
However, significant inter-animal variability was seen in
Fig. 4 Injection of hMSCs does not prevent OA development or progression. Following two consecutive injections of 1 U collagenase over 2 days
(1 U per day), mice were injected with untransduced, AdNull-transduced or AdIL-10-transduced hMSCs (or AdIL-10 virus or vehicle as control) at 1 week
post OA induction. After 6 weeks knees were harvested and analysed for cartilage damage and synovial hyperplasia. a, b Median damage scores in the
medial and lateral femur (maximum score of 6 with three blinded observers, approximately six sections per knee). c, d Median damage scores in the
medial and lateral tibia compartments (maximum score of 6 with three blinded observers, approximately six sections per knee). e Total damage within
the four joint compartments (maximum score of 24). f, g Median scores of synovial hyperplasia in the medial and lateral synovial compartments
(maximum score of 3 with three blinded observers, approximately six sections per knee). Mild OA was observed in all groups with no significant
reduction in the treated groups. Overall there appeared to be more damage in the medial compartment. n = 8 animals per group. MSC mesenchymal
stem cell, OA osteoarthritis
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AdIL-10 MSCs for cartilage and synovium changes in
the medial compartment (Fig. 4a, c) and synovial hyper-
plasia in the lateral compartment (Fig. 4f ). Histologically,
joints with high scores presented with significant osteo-
phyte formation and loss of medial compartment cartil-
age (Fig. 5b). This appeared to occur more in the
hMSC-treated knees, irrespective of whether the cells
were transduced or not. The same pattern was observed
in the synovial damage scores, with more inflammation
observed in the samples that received injections of
hMSCs compared with vehicle (Fig 4f, g). Although not
significant, joints treated with AdIL-10-transduced MSCs
showed less synovial changes compared with the MSC-
treated and AdNull MSC-treated joints. Ultimately,
groups with the least damage were those that were treated
with vehicle or with virus only (Fig. 4e).
Discussion
Recently it has become clear that OA is a disease of the
entire joint and not simply the cartilage [35]. Increasing
evidence highlights the association between factors
produced by inflamed synovium and the initiation and
progression of the disease. Furthermore, inflammation of
the synovial membrane with increased vascular density
and cellular infiltration is a prominent feature of OApathogenesis [36]. The aim of this research was to in-
vestigate the potential of vIL-10-overexpressing hMSCs
to mitigate this inflammation, via modulation of the
immune response and to assess whether this modulation
could delay or prevent the OA onset and progression.
It is clear from the literature that T lymphocytes play
a role in the pathogenesis of OA [37] with cellular
infiltration of the synovial tissue leading to induction of
inflammatory factors [4, 5, 38] and osteoclastogenesis
[6]. Hsieh et al. [39] have shown that CD8 knockout
animals exhibit reduced OA, and an increase in the
presence of CD3+ cells has been demonstrated in the
synovium of osteoarthritic animals [40]. Furthermore,
many T-cell-associated factors, such as IL-17, have
been shown to have negative effects upon joint cartil-
age [4, 41, 42]. While synovial inflammation is higher
in rheumatoid arthritis compared with OA, osteoarthritic
knees still have higher levels of inflammation compared
with healthy controls [43]. Here we clearly demonstrate
that the injection of vIL-10-overexpressing hMSCs leads
to long-term reductions in the numbers of CD4+ and
CD8+ T cells in the draining popliteal lymph nodes of
the knees and activated CD4+ and CD8+ T cells in
the inguinal lymph nodes. Also, injection of AdIL-10
virus alone led to similar outcomes in the levels of
activated CD4+ cells in the popliteal lymph nodes.
AD E
B C
Fig. 5 Representative images showing mild to severe OA. Representative thionine-stained sections of the median scoring knee from each condition:
a vehicle, b Ad-IL10 only, c MSCs only, d AdNull MSCs and e Ad-IL10 MSCs. Erosion of the cartilage, osteophyte formation and synovial hyperplasia is
visible in several of the images. Each image illustrates the medial compartment. FC femoral condyle, TC tibial condyle, S synovium, Op osteophyte.
Scale bar =250 μm
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reductions being observed 6 weeks after injection of
hMSCs.
IL-10 is a pleiotropic cytokine that has been shown to
have positive effects on the synthesis of collagen type II
and aggrecan as well as reducing secretion of pro-
inflammatory cytokines [44]. However, IL-10 has also been
shown to induce proliferation and promote chondrogenic
or hypertrophic differentiation of primary chondrocytes,
highlighting a role for IL-10 in endochondral bone growth
[45]. Elevated levels of IL-10 have been detected in cartil-
age, synovium and subchondral bone explants of patients
with OA [46]. Despite the fact that IL-10 appears to play a
protective role on cartilage in the joint, we did not observe
a direct effect of vIL-10 overexpression on structural
changes within the joint during development of OA. Fur-
ther investigation is therefore required to evaluate the
chondroprotective potential of vIL-10 and its ability to at-
tenuate progression of OA. There is also the possibility
that the presence of IL-10 in the osteoarthritic joint could
lead to further cellular hypertrophy and a negative out-
come since it is also associated with endochondral ossifi-
cation [45]. However, no increased joint damage was seen
in either vIL-10-treated group compared with the others.
While it was not the focus of the study to understand sub-
chondral bone changes, we cannot discount that there
may have been differences in this region in vIL-10-treated
animals. Furthermore, the effects of the inflammatory en-
vironment upon bone could be very different from those
on cartilage. As such it is possible that this treatment,
which had no clear effect on the joint cartilage, may have
had subtle effects on the surrounding bone tissues.MSCs are known to produce a host of paracrine
factors that can reduce inflammation and induce tissue
repair in a number of models [47]. However, whether
they induce joint repair or simply reduce pain is not
completely clear. It does appear that their mechanism of
action is more related to paracrine effects and reduction
of inflammation rather than by direct tissue generation/re-
generation [48]. The exact efficacy of these MSCs in pre-
vention or reversal is still unclear. While there have been
some promising reports relating to the reduction of pain
and even the repair of defects within the joint by MSCs,
longer term and more comprehensive clinical trials are re-
quired in order to clearly identify the efficacy of MSC
therapy. Schurgers et al. [49] previously reported differen-
tial effects of MSCs on T-cell proliferation in vitro vs
in vivo using a collagen-induced arthritis (CIA) model. In
contrast to these findings, we observed a decrease in T
lymphocytes in vitro and in vivo in our OA model follow-
ing treatment with hMSCs transduced to express vIL-10.
However, even though we did not observe an immuno-
genic effect of untransduced or virally transduced hMSCs
on mouse cells in vitro, we did observe that the majority
of the severely damaged knees were in groups treated with
the hMSCs or transduced hMSCs. Interestingly, fully gen-
etically mismatched allogeneic MSCs have been shown to
hold less immunosuppressive activity compared with a
syngeneic or partially mismatched cell source, and have
aggravated disease pathogenesis in a murine CIA model
[50]. We hypothesise that our findings may be due to the
xenogeneic nature of MSCs used in this study. It is
possible that while there was a reduction in the levels of
immune cells present and also in the TNF-α levels in vitro,
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xenogeneic effects. Once again the effects on the bone
density were not assessed and these effects should be taken
into account for studies.
Our study has some limitations. Despite our observa-
tion of a long-term effect of vIL-10-overexpressing
hMSCs on the T-cell number, we did not observe a large
effect of this treatment on the severity and progression
of OA. There are several possible reasons for this lack of
effect on the severity and progression of OA. Firstly, the
model used was designed to lead to mild OA. However,
the degree of progression of the disease was slower/
milder than expected at this time point based on pilot
data (data not shown). Also there were large differences
between animals in the levels of OA and joint damage.
This led to a large amount of variation within and be-
tween groups. It is possible that a clearer picture might
emerge with a slightly more severe OA model, larger
animal numbers or a longer period between cell injec-
tion and joint harvest.
Conclusions
We present a long-term immunomodulatory effect of
vIL-10-overexpressing hMSCs injected into the knees of
osteoarthritic mice. While there was no clear reduction
in disease onset or progression, we believe that this
approach could be used in combination with reparative
approaches to result in a long-term reduction in joint
inflammation. As stated above, T lymphocytes are the
most abundant infiltrating immune cells present in OA
synovium and a role for CD4+ T cells in the pathogen-
esis of OA has been elucidated (refs). Based on the re-
duction in activated T cells present in the draining lymph
nodes of the knees, we believe that, in instances of OA
with a high inflammatory component, treatment with a
combination of syngeneic or perhaps allogeneic MSCs
and vIL-10 could help to reduce symptoms and disease
progression. We also feel that the results presented do
somewhat call into question the use of xenogeneic cells
for the investigation of MSC-mediated repair/protection
of the joint following OA induction. This should be con-
sidered in the execution of similar experiments in the
future.
Additional files
Additional file 1: Figure S1. Timeline illustrating the induction of OA in
mice followed by injection of five different treatment conditions at day 7. Six
weeks after treatment animals were euthanised and the joints harvested for
histological scoring. Lymph nodes and blood were taken for flow cytometric
and multiplex ELISA analyses respectively. (PDF 9 kb)
Additional file 2: Figure S2. Representative safranin O-stained sections
of the median scoring knee from each condition as well as an untreated
contralateral knee for comparison: A Vehicle, B Ad-IL10 only, C MSCs only,
D AdNull MSCs, E Ad-IL10 MSCs and F untreated contralateral knee.Erosion of the cartilage, osteophyte formation and synovial hyperplasia
is visible in several of the images. Each image illustrates the medial
compartment. FC femoral condyle, TC tibial condyle, S synovium,
Op osteophyte. Scale bar =250 μm. (PDF 197 kb)
Additional file 3: Figure S3. AdIL-10-transduced MSCs do not
reduce the levels of pro-inflammatory monocytes at 6 weeks post injection.
A CD11b and Ly6C expression by myeloid cells isolated from the popliteal
and inguinal lymph nodes at 6 weeks post treatment, as detected by flow
cytometry. For the popliteal lymph nodes, data points represent n = 4,
pooled from eight animals. Data points in the AdIL-10 group represent n= 5,
with three samples pooled from two animals and two single samples. For
inguinal lymph nodes, data points represent n= 2, pooled from eight animals.
Data points in the AdIL-10 group represent n= 3, with one sample pooled
from four animals, one sample pooled from three animals and one single
sample. B Serum levels of MCP-1 at 6 weeks post treatment, as quantified
utilising a chemiluminescent array. (PDF 47 kb)
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